Filing Details

Accession Number:
0000899243-17-025463
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-06 19:45:01
Reporting Period:
2017-11-06
Accepted Time:
2017-11-06 19:45:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1624658 Allena Pharmaceuticals Inc. ALNA () E9
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1407577 L.p. Institutional Vii Partners Venture Bessemer C/o Bessemer Venture Partners
1865 Palmer Avenue, Suite 104
Larchmont NY 10538
No No Yes No
1459524 Bvp Vii Special Opportunity Fund Lp C/o Bessemer Venture Partners
1865 Palmer Avenue, Suite 104
Larchmont NY 10538
No No Yes No
1534338 L.p. Vii Partners Venture Bessemer C/o Bessemer Venture Partners
1865 Palmer Avenue, Suite 104
Larchmont NY 10538
No No Yes No
1540726 Deer Vii & Co. Ltd. C/o Bessemer Venture Partners
1865 Palmer Avenue, Suite 104
Larchmont NY 10538
No No Yes No
1540731 Deer Vii & Co. L.p. C/o Bessemer Venture Partners
1865 Palmer Avenue, Suite 104
Larchmont NY 10538
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-06 2,227,365 $0.00 2,227,365 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2017-11-06 36,000 $14.00 2,263,365 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2017-11-06 6,122,448 $0.00 1,466,800 $0.00
Common Stock Series B Preferred Stock Disposition 2017-11-06 3,174,603 $0.00 760,565 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Represents the total shares received by Bessemer Venture Partners VII Institutional L.P. ("BVP VII Inst"), Bessemer Venture Partners VII, L.P. ("BVP VII") and BVP VII Special Opportunity Fund L.P. ("BVP VII SOF" and together with BVP VII Inst and BVP VII, collectively, the "Funds") upon conversion of the Series A Preferred Stock and Series B Preferred Stock upon closing of the Issuer's initial public offering. Following the reported transaction, BVP VII Inst, BVP VII and BVP VII SOF owned 311,829 shares, 712,757 shares and 1,202,779 shares of Common Stock, respectively.
  2. The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 4.174-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  3. Deer VII & Co. Ltd. ("Deer Ltd.") is the general partner of Deer VII & Co. L.P. ("Deer L.P."), which is the general partner of BVP VII Inst, BVP VII and BVP VII SOF. Deer Ltd. and Deer L.P. disclaim beneficial ownership of the securities held by the Funds, and this report shall not be deemed an admission that Deer Ltd. and Deer L.P. are the beneficial owners of such securities, except to the extent of their pecuniary interest therein, if any, by virtue of their direct and indirect general partner interests in the Funds.
  4. On November 6, 2017, BVP VII Inst, BVP VII and BVP VII SOF purchased 5,040 shares, 11,520 shares and 19,440 shares of Common Stock, respectively, at a price per share of $14.00 in the Issuer's initial public offering. Following the reported transaction, BVP VII Inst, BVP VII and BVP VII SOF owned 316,869 shares, 724,277 shares and 1,222,219 shares of Common Stock, respectively.
  5. Prior to the conversion, BVP VII Inst, BVP VII and BVP VII SOF owned 857,143 shares, 1,959,184 shares and 3,306,121 shares of Series A Preferred Stock, respectively.
  6. Prior to the conversion, BVP VII Inst, BVP VII and BVP VII SOF owned 205,350 shares, 469,376 shares, and 792,074 shares, respectively, of Common Stock issuable upon conversion of the Series A Preferred Stock.
  7. Prior to the conversion, BVP VII Inst, BVP VII and BVP VII SOF owned 444,444 shares, 1,015,873 shares and 1,714,286 shares of Series B Preferred Stock, respectively.
  8. Prior to the conversion, BVP VII Inst, BVP VII, and BVP VII SOF owned 106,479 shares, 243,381 shares, and, 410,705 shares, respectively, of Common Stock issuable upon conversion of the Series B Preferred Stock.